Medpace bucks negative IPO trend as it raises high end of its range

Medpace has raised $161 million in its initial public offering, the top end of the CRO’s desired range, despite persistent headwinds for other sectors including biotech.

The Cincinnati, OH-based company, which made $332 million in the previous financial year, had been owned by investment firms Cinven and MPI, who held about 75% and 25% of the company respectively.

This exit to the public markets is a fast turnaround for Cinven, which bought Medpace from private equity firm CCMP Capital Advisors back in 2014 for around $900 million.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The CRO sold 7 million shares at $23--the high end of the range of $20 to $23. Medpace said in a statement that it plans to list on the Nasdaq under the symbol "MEDP."

The company added that it intends to “use the net proceeds of this offering to repay a portion of its outstanding borrowings under its senior secured term loan facility.”

- check out the release

Related Articles:
Medpace seeks $151M IPO; says CRO industry worth $31B by decade’s end
Medpace seeking $1B public offering: Reuters

Read more on

Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.